![Bruno Reihl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Provenance du réseau au premier degré de Bruno Reihl
Entité | Type d'entité | Industrie | |
---|---|---|---|
Luciole Medical AG
![]() Luciole Medical AG Packaged SoftwareTechnology Services Luciole Medical AG operates as a Swiss medical technology company developing brain oxygenation monitoring systems. The firm's products include Rheopatch, RheoSens, RheoLity and RheoControl. The company was founded in September 2017 and is headquartered in Zurich, Switzerland.
3
| Holding Company | Packaged Software | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Bruno Reihl via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
ANTARES PHARMA, INC. | Pharmaceuticals: Major | Chief Operating Officer | |
SpineVision SA
![]() SpineVision SA Medical SpecialtiesHealth Technology SpineVision SA develops and markets implants for the treatment of spinal disorders. It also designs instrumentation for the spinal treatments. Its products include Flex 2, Lumis, Plus/X-Plus, ULIS, Unithread, Spacevisions, and C3. The firm also offers solutions for spinal pathologies, such as lumbar degenerative disc diseases, deformities, cervical disorders, trauma, and tumors. The company was founded by Gérard Vanacker on July 16, 1999 and is headquartered in Antony, France. | Medical Specialties | Director/Board Member | |
NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal | |
Axovan AG
![]() Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Miscellaneous Commercial Services | Founder | |
Cranfield University | College/University | Masters Business Admin | |
École Normale Supérieure de Lyon | College/University | Masters Business Admin | |
University of Grenoble | College/University | Doctorate Degree | |
Themis Bioscience GmbH
![]() Themis Bioscience GmbH Pharmaceuticals: MajorHealth Technology Themis Bioscience GmbH operates as a biotechnology company, which engages in the development of prophylactic vaccinations from preclinical to early clinical phase. The firm focuses on the prevention of tropical infectious diseases. Its proprietary Themaxyn technology platform, in-licensed from Paris-based Institute Pasteur, forms the basis of all of the company's vaccine candidates. The company was founded by Erich Tauber in 2009 and is headquartered in Vienna, Austria. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Aleva Neurotherapeutics SA
![]() Aleva Neurotherapeutics SA Electronic Equipment/InstrumentsElectronic Technology Aleva Neurotherapeutics SA develops next-generation implants for deep brain stimulation therapy. Its micro fabricated devices enable target specific stimulation and optimization of current therapies. The company was founded by Claudio Pollo, Jean-Pierre Rosat, Philipe Renaud, Paul Pyzowski and André Mercanzini and in August 2008 and is headquartered in Lausanne, Switzerland. | Electronic Equipment/Instruments | Director/Board Member | |
Mestex AG
![]() Mestex AG Pharmaceuticals: MajorHealth Technology Part of Grünenthal Pharma GmbH & Co. KG, Mestex AG is a Swiss pharmaceutical manufacturing company. The company is based in Basel, Switzerland. The CEO of the company is Olivier Valdenaire. Mestex was acquired by Grünenthal GmbH on April 12, 2021. | Pharmaceuticals: Major | Chairman | |
Scenic Biotech BV
![]() Scenic Biotech BV Miscellaneous Commercial ServicesCommercial Services Scenic Biotech BV is using genomics to develop innovative therapies for patients affected by severe diseases. The company was founded by Thijn Brummelkamp and Sebastian Nijman and is headquartered in Amsterdam, Netherlands. | Miscellaneous Commercial Services | Chairman | |
Bouche Pere et Fils
![]() Bouche Pere et Fils Agricultural Commodities/MillingProcess Industries Bouche Pere et Fils cultivates vineyards. The private company is based in Pierry, France. The CEO of the French company is Nicolas Bouche. | Agricultural Commodities/Milling | Chief Executive Officer | |
LimmaTech Biologics AG
![]() LimmaTech Biologics AG Miscellaneous Commercial ServicesCommercial Services LimmaTech Biologics AG is a clinical stage biopharmaceutical company based in Schlieren, Switzerland. LimmaTech Biologics is dedicated to combating the antimicrobial resistance epidemic by developing vaccines using its proprietary self-adjuvanting and multi-antigen vaccine platform, alongside additional disease-specific vaccine approaches. The Swiss company has decades of expertise and an expanding pipeline, and is focused on generating protective solutions to deliver transformative value worldwide. The company was founded in 2015 by Philippe Dro, Michael Wacker, Paul Wolfarm, Michael Kowarik, Veronica Gambillara Fonck. Franz-Werner Haas has been the CEO of the company since 2023. | Miscellaneous Commercial Services | Founder | |
Adjuvant Capital | Investment Managers | Private Equity Investor | |
GlycoEra AG
![]() GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Biotechnology | Director/Board Member |
Statistiques
Internationale
Suisse | 10 |
France | 4 |
Royaume-Uni | 3 |
Etats-Unis | 2 |
Autriche | 2 |
Sectorielle
Health Technology | 10 |
Commercial Services | 4 |
Consumer Services | 4 |
Electronic Technology | 2 |
Process Industries | 2 |
Opérationnelle
Director/Board Member | 7 |
Chairman | 4 |
Chief Executive Officer | 3 |
Founder | 3 |
Chief Operating Officer | 3 |
Relations les plus connectées
Insiders | |
---|---|
Philippe Dro | 18 |
Nicolas Bouche | 2 |
Markus Muser | 1 |
- Bourse
- Insiders
- Bruno Reihl
- Connexions Sociétés